Paclitaxel and Cisplatin for Thymic Neoplasm

Inclusion Criteria: * histologically or cytologically confirmed invasive thymoma or thymic carcinoma * unresectable tumor: by either local invasion, distant metastasis, or recurred (assessed by investigator) * no previous systemic treatment for invasive thymoma or thymic carcinoma * at least one measurable lesion by RECIST criteria * 18 years old or older * ECOG performance status 0, 1, 2 * adequate lab. findings neutrophil ≥ 1.5 x 10\^9/L platelet ≥ 75 x 10\^9/L hemoglobin ≥ 9.0 g/dL bilirubin ≤ 1.5 x upper normal limit AST, ALT ≤ 2.5 x upper normal limit Alkaline phosphatase ≤ 2.5 x upper normal limit (if liver metastasis, ≤ 5 x upper normal limit) serum creatinine ≤ 1.0 x upper normal limit if serum creatinine \> 1.0 x upper normal limit, creatinine clearance ≥ 60 mL/min * patient who agree to written, informed consent Exclusion Criteria: * other malignancy (exception: non-melanoma skin cancer, cervical carcinoma in situ, cancer without evidence more than 5 years since curative resection) * active bacterial infection * history of clinical trial with investigational drug within 30 days * radiotherapy to thoracic or mediastinal area (other area radiotherapy is permitted) * pregnant, or lactating women * patient with organ transplantation * peripheral neuropathy, grade 2 or greater * severe, medical condition unstable cardiac disease despite of adequate management myocardial infarction within 6 months active ulcer disease refractory to medication chronic obstructive lung disease requiring admission treatment within 1 year * uncontrolled seizure, cerebral nervous system disorder, psychiatric problem which decrease treatment compliance